公开(公告)号：WO2014145342A2

公开(公告)日：2014-09-18

申请号：PCT/US2014/030082

申请日：2014-03-15

Applicant: CODA THERAPEUTICS, INC.

Inventor： PHILLIPS, Anthony ,  EISENBUD, David ,  BANNAN, Scott ,  POOL, David ,  MATSUOKA, Grove ,  SUNDERLAND, Tracey ,  DUFT, Bradford

IPC: H04S5/00

CPC classification number: A61K31/7088 ,  A61B5/0064 ,  A61B5/0077 ,  A61B5/1072 ,  A61B5/1079 ,  A61B5/1109 ,  A61B5/445 ,  A61B5/4839 ,  A61B5/4848 ,  A61B5/7275 ,  A61B2503/40 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/70 ,  A61K31/7105 ,  A61K47/00 ,  A61K47/10 ,  A61K47/38 ,  A61K48/00 ,  C07K14/47 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2320/30 ,  C12N2320/35

Abstract: This invention concerns improved methods, uses, and kits for treating chronic wounds through the administration of anti-connexin agents, particularly anti-connexin 43 antisense polynucleotides. The methods, uses, and kits of the invention are based on the surprising and unexpected discovery that chronic wounds that do not increase or decrease in size by more than a pre-determined amount during a pre-treatment phase are more amenable to successful treatment than wounds whose size varies outside the target range during the pre-treatment phase.

Abstract translation: 本发明涉及通过施用抗连接蛋白试剂，特别是抗连接蛋白43反义多核苷酸来治疗慢性伤口的改进的方法，用途和试剂盒。 本发明的方法，用途和试剂盒基于令人惊讶且意外的发现，即在预处理阶段期间不增加或减小超过预定量的慢性伤口更适于成功治疗 伤口的大小在预处理阶段期间超出目标范围。

公开(公告)号：EP2970967A2

公开(公告)日：2016-01-20

申请号：EP14764924.8

申请日：2014-03-15

Applicant: CoDa Therapeutics, Inc.

Inventor： PHILLIPS, Anthony ,  EISENBUD, David ,  BANNAN, Scott ,  POOL, David ,  MATSUOKA, Grove ,  SUNDERLAND, Tracey ,  DUFT, Bradford

IPC: C12N15/11 ,  C12N5/00 ,  C12N5/02

CPC classification number: A61K31/7088 ,  A61B5/0064 ,  A61B5/0077 ,  A61B5/1072 ,  A61B5/1079 ,  A61B5/1109 ,  A61B5/445 ,  A61B5/4839 ,  A61B5/4848 ,  A61B5/7275 ,  A61B2503/40 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/70 ,  A61K31/7105 ,  A61K47/00 ,  A61K47/10 ,  A61K47/38 ,  A61K48/00 ,  C07K14/47 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2320/30 ,  C12N2320/35

Abstract: This invention concerns improved methods, uses, and kits for treating chronic wounds through the administration of anti-connexin agents, particularly anti-connexin 43 antisense polynucleotides. The methods, uses, and kits of the invention are based on the surprising and unexpected discovery that chronic wounds that do not increase or decrease in size by more than a pre-determined amount during a pre-treatment phase are more amenable to successful treatment than wounds whose size varies outside the target range during the pre-treatment phase.